By Paul Girouard
Infection prevention in 2025 was defined by transition – in policy, personnel, and public health priorities. At the same time, evolving disease threats – from resurgent measles and H5N1 to a tougher flu season – reinforced the critical role of infection preventionists (IPs), clinicians, and sales professionals on the front lines.
The following article examines how the infection prevention landscape adapted to new challenges, how vaccine policy evolved, and how sales professionals helped bridge the gap between regulation and real-world implementation.
A year of change in public health leadership
Significant changes within the U.S. Department of Health and Human Services (HHS) had ripple effects across key federal agencies. According to Reuters, a major restructuring effort resulted in approximately 10,000 staff reductions across the CDC, FDA, and NIH. In October, CIDRAP and Infection Control Today reported that the CDC experienced a 33% workforce reduction, impacting divisions such as immunization, global health, and infection prevention.
Earlier in the year, the Healthcare Infection Control Practices Advisory Committee (HICPAC) was disbanded, drawing concern from healthcare professionals and associations due to its historic role in guiding infection prevention policies. These structural changes introduced uncertainty into national-level coordination of infection control practices.
Evolving health threats and vaccine policy
Throughout 2025, multiple disease outbreaks kept infection prevention top of mind. Measles cases rose in certain regions, zoonotic threats like H5N1 resurfaced, and seasonal influenza activity was more severe than expected in some areas. The World Health Organization continued to advocate for strong national IPC programs as part of the global strategy to combat antimicrobial resistance.
At the same time, U.S. vaccination guidance underwent revisions. The CDC updated its immunization schedule, offering more flexibility for COVID-19 boosters and recommending the MMRV (measles, mumps, rubella, varicella) combination vaccine be split into individual components for toddlers. These updates reflected a shift toward individualized decision-making and highlighted the growing role of local providers in communicating vaccine strategy.
Increased reliance on local and facility-based protocols
As federal guidance evolved, many healthcare systems took a more localized approach to infection prevention. Organizations such as APIC (Association for Professionals in Infection Control and Epidemiology) and AORN (Association of periOperative Registered Nurses) played a greater role in educating frontline staff and sharing updated best practices. Campaigns like WHO’s “Clean Your Hands 2025” kept focus on hand hygiene and glove use compliance.
Sales representatives and infection prevention
For distributors and field sales reps, 2025 highlighted the importance of supporting infection prevention beyond just product fulfillment. The most successful reps:
- Provided education around regulatory drivers, such as CMS penalties for HAIs.
- Helped implement compliant product solutions, particularly hand hygiene and single-use instruments.
- Partnered with IPs and nurse educators to offer training and in-servicing.
- Leveraged manufacturer support teams to supply clinical data and ROI tools that resonated with both procurement and clinical teams.
Recommended resources for new sales representatives:
- CDC HAI Prevention Tools: www.cdc.gov/hai
- APIC Resource Library: www.apic.org/Professional-Practice/Resource-Library
- CMS Infection Control Standards: www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Policy-and-Memos-to-States-and-Regions
- WHO IPC Guidance: www.who.int/teams/integrated-health-services/infection-prevention-control
- HIDA Insights on Infection Prevention: www.hida.org
Looking ahead
As infection risks persist and federal staffing transitions continue into 2026, local leadership in infection prevention will remain essential. For sales professionals, this presents an opportunity to move from a transactional to a strategic partner – by aligning products with protocols and supporting outcomes.
Wash your hands.
Key insights from 2025:
- The U.S. infection prevention market reached an estimated $52 billion, with 6% to 7% projected annual growth.
- Federal agencies experienced major staffing reductions, impacting national infection prevention coordination.
- Public health events (measles, H5N1, influenza) increased infection risk and response urgency.
- Vaccination policy changes emphasized individualized decision-making.
- Local facilities, infection preventionists, and distributors played a growing role in education, implementation, and support.